Valerie Touitou

Valerie Touitou

Auto-generated profile, based on publicly available information

Valerie Touitou

Ophthalmology Department, Sorbonne Université, AP-HP, Pitie-Salpetriere University Hospital, Paris, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
CHCaroline Houillier
Caroline Houillier
CSCarole Soussain
Carole Soussain
HGHervé Ghesquières
Hervé Ghesquières
PSPierre Soubeyran
Pierre Soubeyran
OCOlivier Chinot
Olivier Chinot
EGEmmanuel Gyan
Emmanuel Gyan
Objective Real-life studies on patients with primary CNS lymphoma (PCNSL) are scarce. Our objective was to analyze, in a nationwide population-based study, the current medical practice in the management of PCNSL. Methods The French oculo-cerebral lymphoma network (LOC) database prospectively records all newly diagnosed PCNSL cases from 32 French centers. Data of patients diagnosed between 2011 and 2016 were retrospectively analyzed. Results We identified 1,002 immunocompetent patients (43% aged >70 years, median Karnofsky Performance Status [KPS] 60). First-line treatment was high-dose methotrexate-based chemotherapy in 92% of cases, with an increasing use of rituximab over time (66%). Patients 60 years of age, WBRT and HCT-ASCT consolidation were administered in only 9% and 2%, respectively. The complete response rate to initial chemotherapy was 50%. Median progression-free survival was 10.5 months. For relapse, second-line chemotherapy, HCT-ASCT, WBRT, and palliative care were offered to 55%, 17%, 10%, and 18% of patients, respectively. The median, 2-year, and 5-year overall survival was 25.3 months, 51%, and 38%, respectively (60 years: 15.4 months, 44%, and 28%). Age, KPS, sex, and response to induction CT were independent prognostic factors in multivariate analysis. Conclusions Our study confirms the increasing proportion of elderly within the PCNSL population and shows comparable outcome in this population-based study with those reported by clinical trials, reflecting a notable application of recent PCNSL advances in treatment.

10 November 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CHCaroline Houillier
Caroline Houillier
SDSylvain Dureau
Sylvain Dureau
LTLuc Taillandier
Luc Taillandier
RHRoch Houot
Roch Houot
OCOlivier Chinot
Olivier Chinot
OLOn Behalf Of The Loc Network For Cns Lymphoma
On Behalf Of The Loc Network For Cns Lymphoma
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We previously reported the results of a randomized phase II study in patients with newly diagnosed primary CNS lymphoma (age 18-60 years). Patients were treated with high-dose methotrexate-based induction chemotherapy followed by whole-brain radiotherapy (WBRT) or high-dose chemotherapy (thiotepa-busulfan-cyclophosphamide) with autologous stem-cell transplantation (ASCT). The median follow-up was 33 months. In this report, we provide long-term data (median follow-up, 8 years) regarding the outcomes and toxicities. Fifty-three and 44 patients received induction chemotherapy followed by WBRT or ASCT, respectively. Their 8-year event-free survival from random assignment was 67% and 39% in the ASCT and WBRT arms, respectively ( P = .03), with a significantly lower risk of relapse after ASCT (hazard ratio, 0.13; P < .001). One third of patients who relapsed after WBRT were alive after salvage treatment. Five and four patients died of ASCT and WBRT-related toxicities, respectively. The 8-year overall survival was 69% and 65% in the ASCT and WBRT arms, respectively (not significant). Balance (52% v 10%, P ≤ 0.001) and neurocognition (64% v 13%, P < .001) significantly deteriorated after WBRT compared with ASCT during the follow-up. This study shows that 40 Gy WBRT should be avoided in first-line treatment because of its neurotoxicity and suboptimal efficacy in reducing relapses while ASCT appears to be highly efficient in preventing relapses.

17 April 2021 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
MLMarion Lam
Marion Lam
VTValérie Touitou
Valérie Touitou
SCSylvain Choquet
Sylvain Choquet
NCNathalie Cassoux
Nathalie Cassoux
HGHervé Ghesquières
Hervé Ghesquières
CHCaroline Houillier
Caroline Houillier
The treatment of primary vitreoretinal lymphoma (PVRL) remains controversial regarding the use of local, systemic, or combined treatments. The aim of this study was to analyze the efficacy and toxicity of intravenous high‐dose methotrexate (IV HD‐MTX) based systemic therapy in a uniformly treated population of PVRL patients. From a nationwide French database, we retrospectively selected 59 patients (median age: 70 years, median Karnofsky Performance Status: 90%) with isolated PVRL at diagnosis who received first‐line treatment with HD‐MTX between 2011 and 2018. 8/59 patients also received a local treatment. No deaths or premature discontinuations of MTX due to toxicity were reported. A complete response was obtained in 40/57 patients after chemotherapy. Before treatment, IL‐10 was elevated in the aqueous humor (AH) or in the vitreous in 89% of patients. After treatment, AH IL‐10 was undetectable in 87% of patients with a CR/uCR/PR and detectable in 92% of patients with PD/SD. After a median follow‐up of 61 months, 42/59 (71%) patients had relapsed, including 29 isolated ocular relapses as the first relapse and a total of 22 brain relapses. The median overall survival, progression‐free survival, ocular‐free survival and brain‐free survival were 75, 18, 29 and 73 months, respectively. IV HD‐MTX based systemic therapy as a first‐line treatment for isolated PVRL is feasible, with acceptable toxicity, even in an elderly population. This strategy seems efficient to prevent brain relapse with prolonged overall survival. However, the ocular relapse rate remains high. New approaches are needed to improve local control of this disease, and ocular assessment could be completed by monitoring AH IL‐10.

16 October 2013 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
PDF file
EPElise Philippakis
Elise Philippakis
NCNathalie Cassoux
Nathalie Cassoux
FCFrédéric Charlotte
Frédéric Charlotte
PLPhuc LeHoang
Phuc LeHoang
BBBahram Bodaghi
Bahram Bodaghi
VTValérie Touitou
Valérie Touitou
Purpose: To report atypical ophthalmologic manifestations and complications of IgG4-related disease (IgG4-RD). Methods: Patients with isolated ophthalmologic involvement of IgG4-RD other than lacrimal or orbital infiltration seen between 2009 and 2011 in a single tertiary center were retrospectively reviewed and their clinical and histological features, treatment, and prognosis were studied. Case reports: Two patients (mean age 56.5 years) were included. One patient presented with recurrent anterior and posterior scleritis, and one patient had chronic conjunctival infiltration. Histopathology demonstrated lymphoplasmacytic proliferation with overexpression of IgG4+ plasma cells. Both patients initially responded to a high dose of oral corticosteroids (1 mg/kg/d). However, one patient required the adjunction of methotrexate and one patient developed an intra-epithelial conjunctival carcinoma on the site of the initial lesion. Conclusion: Patients with atypical presentation of IgG4-RD, such as chronic conjunctival infiltration or scleritis, can suffer from considerable diagnostic delay leading to fibrosis or malignancy development. We report the first case of conjunctival carcinoma in a patient with IgG4-RD.

1 September 2016 in Ophthalmology
Verified
Journal Article
Closed access
DNDiem-Trang Nguyen
Diem-Trang Nguyen
CHCaroline Houillier
Caroline Houillier
SCSylvain Choquet
Sylvain Choquet
NCNathalie Cassoux
Nathalie Cassoux
CSCarole Soussain
Carole Soussain
VTValérie Touitou
Valérie Touitou

14 February 2014 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
VTValerie Touitou
Valerie Touitou
BBBahram Bodaghi
Bahram Bodaghi
STSylvain Thépot
Sylvain Thépot
ECElise Chapiro
Elise Chapiro
FNFlorence Nguyen‐Khac
Florence Nguyen‐Khac
KMKarim Maloum
Karim Maloum
Click on the article title to read more.